Atara Biotherapeutics Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,800 shares of the business’s stock in a transaction on Friday, October 14th. The shares were sold at an average price of $15.96, for a total transaction of $76,608.00. Following the transaction, the chief executive officer now owns 549,136 shares of the company’s stock, valued at $8,764,210.56. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) opened at 16.15 on Tuesday. Atara Biotherapeutics Inc. has a 1-year low of $13.31 and a 1-year high of $40.80. The firm has a 50-day moving average of $19.53 and a 200 day moving average of $20.24. The company’s market capitalization is $465.30 million.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.05. On average, analysts anticipate that Atara Biotherapeutics Inc. will post ($2.85) EPS for the current year.
ATRA has been the subject of a number of recent analyst reports. Jefferies Group restated a “buy” rating and set a $25.00 price target on shares of Atara Biotherapeutics in a research report on Tuesday, August 9th. JMP Securities restated a “buy” rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 2nd. Goldman Sachs Group Inc. lowered shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and reduced their price target for the company from $23.00 to $16.00 in a research report on Thursday, September 15th. Finally, Citigroup Inc. boosted their price target on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a research report on Friday, August 19th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $26.14.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bridger Management LLC acquired a new position in Atara Biotherapeutics during the first quarter valued at $14,072,000. FMR LLC increased its stake in shares of Atara Biotherapeutics by 29.9% in the second quarter. FMR LLC now owns 3,125,407 shares of the company’s stock valued at $70,353,000 after buying an additional 720,313 shares during the last quarter. Slate Path Capital LP purchased a new stake in shares of Atara Biotherapeutics during the second quarter valued at approximately $9,454,000. BlackRock Fund Advisors increased its stake in shares of Atara Biotherapeutics by 18.6% in the second quarter. BlackRock Fund Advisors now owns 913,922 shares of the company’s stock valued at $20,572,000 after buying an additional 143,242 shares during the last quarter. Finally, Redmile Group LLC increased its stake in shares of Atara Biotherapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 2,408,970 shares of the company’s stock valued at $54,226,000 after buying an additional 133,205 shares during the last quarter. Institutional investors and hedge funds own 75.58% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.